Imatinib Mesylate (generic for Gleevec®)
For the 7 indications it has been approved for by the F.D.A., Imatinib Mesylate is the generic equivalent for Gleevec and is immediately available for prescription order from Onco360.
Order Imatinib Mesylate from Onco360
3 Easy Ways to Order:
e-Prescribe
Oncomed Dba Onco360 or
NPI# 1679618151
Call
Onco360 Imatinib Mesylate Generic Medication Guide:
Imatinib Mesylate is a kinase inhibitor approved for the treatment of the following 7 indications:
| Approved Indications1 |
| 1. Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase |
| 2. Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy |
| 3. Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) |
| 4. Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements |
| 5. Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown |
| 6. Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown |
| 7. Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP) |
Dosage and Administration:
Imatinib Mesylate is an oral medication available in 100 mg and 400 mg strength tablets.
| Patient Type/Indication1 | Recommended Dosage1 |
| Adults with Ph+ CML CP | 400 mg/day |
| Adults with Ph+ CML AP or BC | 600 mg/day |
| Pediatrics with Ph+ CML CP | 340 mg/m2/day |
| Adults with Ph+ ALL | 600 mg/day |
| Adults with MDS/MPD | 400 mg/day |
| Adults with ASM | 100 mg/day or 400 mg/day |
| Adults with HES/CEL | 100 mg/day or 400 mg/day |
| Adults with DFSP | 800 mg/day |
| Patients with mild to moderate hepatic impairment | 400 mg/day |
| Patients with severe hepatic impairment | 300 mg/day |
1www.imatinibrx.com/wp-content/uploads/2016/01/Imatinib_Mesylate_Tablets_PI.pdf
All rights in the product names, trade names, or logos of all third-party products, whether or not appearing with the registered trademark symbol, belong exclusively to their respective owners.